- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 15, 2024Robins Kaplan Named to 2024 BTI Client Service A-Team
-
April 9, 2024Robins Kaplan LLP Files Complaint Against Social Media Giants Meta, Snap, TikTok on Behalf of Spirit Lake Nation, Menominee Indian Tribe of Wisconsin
-
April 8, 2024Tara Sutton, Emily Tremblay Shortlisted for Euromoney’s Women in Business Law Awards
-
April 24, 2024IP Leadership Executive Summit
-
April 24, 2024IP Odyssey: Navigating the Latest Developments in Intellectual Property Law
-
April 30, 2024Navigating Generational Dynamics
-
March 2024e-Commerce: Pitfalls and Protections
-
March 22, 2024‘In re Cellect’:
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
New ANDA Cases
Winter 2020
| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Belcher Pharms., LLC v. Hospira, Inc., 19-1854 (D. Del.) | Oct. 3, 2019 | Hon. Richard G. Andrews | Abboject® (epinephrine for injection) | 10,004,700 10,039,728 |
| Boehringer Ingelheim Pharms. Inc. v. Aurobindo Pharma Ltd., 19-1862 (D. Del.) | Oct. 3, 2019 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) Glyxambi® (empagliflozin / linagliptin tablets) Synjardy® (empagliflozin / metformin tablets) Synjardy® XR (empagliflozin / metformin extended-release tablets) |
10,258,637 |
| Boehringer Ingelheim Pharms. Inc. v. Macleods Pharms. Ltd., 19-1864 (D. Del.) | Oct. 3, 2019 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) Glyxambi® (empagliflozin / linagliptin tablets) Synjardy® (empagliflozin / metformin tablets) |
10,258,637 |
| Boehringer Ingelheim Pharms. Inc. v. MSN Labs. Private Ltd., 19-1865 (D. Del.) | Oct. 3, 2019 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) Glyxambi® (empagliflozin / linagliptin tablets) Synjardy® XR (empagliflozin / metformin extended-release tablets) |
10,258,637 |
| Boehringer Ingelheim Pharms. Inc. v. Lupin Ltd., 19-1866 (D. Del.) | Oct. 3, 2019 | Hon. Colm F. Connolly | Synjardy® XR (empagliflozin / metformin extended-release tablets) | 9,949998 10,258637 |
| Bristol-Myers Squibb Co. v. Dr. Reddy’s Labs., Ltd., 19-18686 (D.N.J.) | Oct. 3, 2019 | Hon. Michael A. Shipp | Sprycel® (dasatinib tablets) | 7,491,725 8,680,103 |
| Boehringer Ingelheim Pharms. Inc. v. Alembic Pharms. Ltd., 19-1885 (D. Del.) | Oct. 7, 2019 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) Glyxambi® (empagliflozin / linagliptin tablets) Synjardy® (empagliflozin / metformin tablets) |
10,258,637 |
| Chiesi USA, Inc. v. Aurobindo Pharma USA, Inc., 19-18756 (D.N.J.) | Oct. 7, 2019 | Hon. Freda L. Wolfson | Cleviprex® (clevidipine injectable emulsion) | 8,658676 10,010537 |
| Mitsubishi Tanabe Pharma Corp. v. Dr. Reddy’s Labs., Inc., 19-18764 (D.N.J.) | Oct. 7, 2019 | Hon. Freda L. Wolfson | Invokamet® (canagliflozin / metformin HCl tablets) | 7,943,788 |
| Aclaris Therapeutics, Inc. v. Taro Pharms., Inc., 19-1910 (D. Del.) | Oct. 8, 2019 | Hon. Colm F. Connolly | Rhofade® (oxymetazoline HCl cream) | 7,812,049 8,420,688 8,815,929 9,974,773 10,335,391 |
| Celgene Corp. v. Zydus Pharms. (USA) Inc., 19-18806 (D.N.J.) | Oct. 8, 2019 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 8,093,283 8,629,173 |
| Mylan API US LLC v. American Regent, Inc., 19-5675 (E.D.N.Y.) | Oct. 8, 2019 | Hon. Roslynn R. Mauskopf | Isosulfan Blue 1% injection | 9,353,050 |
| Otsuka Pharm. Co., Ltd. v. Zenara Pharma Private Ltd., 19-1938 (D. Del.) | Oct. 11, 2019 | Hon. Leonard P. Stark | Rexulti® (brexpiprazole tablets) | 7,888,362 8,349,840 8,618,109 9,839,637 10,307,419 |
| Otsuka Pharm. Co., Ltd. v. Ajanta Pharma Ltd., 19-1939 (D. Del.) | Oct. 11, 2019 | Hon. Leonard P. Stark | Rexulti® (brexpiprazole tablets) | 7,888,362 8,349,840 8,618,109 9,839,637 10,307,419 |
| Mitsubishi Tanabe Pharma Corp. v. MSN Labs. Private Ltd., 19-18958 (D.N.J.) | Oct. 14, 2019 | Hon. Freda L. Wolfson | Invokana® (canagliflozin tablets) Invokamet XR® (canagliflozin / metformin HCl extended-release tablets) |
7,943,788 |
| Otsuka Pharm. Co., Ltd. v. Amneal Pharms. LLC, 19-1952 (D. Del.) | Oct. 15, 2019 | Hon. Leonard P. Stark | Rexulti® (brexpiprazole tablets) | 7,888,362 8,349,840 8,618,109 9,839,637 10,307,419 |
| Otsuka Pharm. Co., Ltd. v. Hetero Labs Ltd., 19-1954 (D. Del.) | Oct. 15, 2019 | Hon. Leonard P. Stark | Rexulti® (brexpiprazole tablets) | 7,888,362 8,349,840 8,618,109 9,839,637 10,307,419 |
| Otsuka Pharm. Co., Ltd. v. Teva Pharms. USA, Inc., 19-1955 (D. Del.) | Oct. 15, 2019 | Hon. Leonard P. Stark | Rexulti® (brexpiprazole tablets) | 7,888,362 8,349,840 8,618,109 9,839,637 10,307,419 |
| Otsuka Pharm. Co., Ltd. v. Prinston Pharm. Inc., 19-1956 (D. Del.) | Oct. 15, 2019 | Hon. Leonard P. Stark | Rexulti® (brexpiprazole tablets) | 7,888,362 8,349,840 8,618,109 9,839,637 10,307,419 |
| Otsuka Pharm. Co., Ltd. v. Alkem Labs. Ltd., 19-1964 (D. Del.) | Oct. 16, 2019 | Hon. Leonard P. Stark | Rexulti® (brexpiprazole tablets) | 7,888,362 8,349,840 8,618,109 9,839,637 10,307,419 |
| Otsuka Pharm. Co., Ltd. v. Aurobindo Pharma Ltd., 19-1965 (D. Del.) | Oct. 16, 2019 | Hon. Leonard P. Stark | Rexulti® (brexpiprazole tablets) | 7,888,362 8,349,840 8,618,109 9,839,637 10,307,419 |
| Sanofi-Aventis U.S. LLC v. Shilpa Medicare Ltd., 19-1975 (D. Del.) | Oct. 17, 2019 | Hon. Maryellen Noreika | Aubagio® (teriflunomide tablets) | 6,794,410 9,186,346 |
| Otsuka Pharm. Co., Ltd. v. Unichem Labs. Ltd., 19-1977 (D. Del.) | Oct. 17, 2019 | Hon. Leonard P. Stark | Rexulti® (brexpiprazole tablets) | 7,888,362 8,349,840 8,618,109 9,839,637 10,307,419 |
| Novartis Pharms. Corp. v. Alkem Labs. Ltd., 19-1979 (D. Del.) | Oct. 17, 2019 | Hon. Leonard P. Stark | Entresto® (sacubitril / valsartan tablets) | 8,101,659 8,796,331 8,877,938 9,388,134 |
| AstraZeneca Pharms. LP v. Xiromed, LLC, 19-19081 (D.N.J.) | Oct. 17, 2019 | Hon. Renee Marie Bumb | Faslodex® (fulvestrant for injection) | 6,774,122 7,456,160 8,329,680 8,466,139 |
| Par Pharm., Inc. v. Fresenius Kabi USA, LLC, 19-1985 (D. Del.) | Oct. 18, 2019 | Hon. Colm F. Connolly | Vasostrict® (vasopressin for injection) | 9,375,478 9,687,526 9,744,209 9,750,785 9,937,223 |
| Otsuka Pharm. Co., Ltd. v. Accord Healthcare Inc., 19-1987 (D. Del.) | Oct. 18, 2019 | Hon. Leonard P. Stark | Rexulti® (brexpiprazole tablets) | 7,888,362 8,349,840 8,618,109 9,839,637 10,307,419 |
| Otsuka Pharm. Co., Ltd. v. Lupin Ltd., 19-1988 (D. Del.) | Oct. 18, 2019 | Hon. Leonard P. Stark | Rexulti® (brexpiprazole tablets) | 7,888,362 8,349,840 8,618,109 9,839,637 10,307,419 |
| Otsuka Pharm. Co., Ltd. v. Accord Healthcare Inc., 19-1072 (M.D.N.C.) | Oct. 18, 2019 | Hon. Thomas D. Schroeder | Rexulti® (brexpiprazole tablets) | 7,888,362 8,349,840 8,618,109 9,839,637 10,307,419 |
| Otsuka Pharm. Co., Ltd. v. Apotex Inc., 19-2006 (D. Del.) | Oct. 23, 2019 | Hon. Leonard P. Stark | Rexulti® (brexpiprazole tablets) | 10,307,419 |
| Otsuka Pharm. Co., Ltd. v. Alembic Pharms. Ltd., 19-2007 (D. Del.) | Oct. 23, 2019 | Hon. Leonard P. Stark | Rexulti® (brexpiprazole tablets) | 7,888,362 8,349,840 8,618,109 9,839,637 10,307,419 |
| Otsuka Pharm. Co., Ltd. v. Optimus Pharma Pvt. Ltd., 19-2008 (D. Del.) | Oct. 23, 2019 | Hon. Leonard P. Stark | Rexulti® (brexpiprazole tablets) | 7,888,362 8,349,840 8,618,109 9,839,637 10,307,419 |
| Otsuka Pharm. Co., Ltd. v. MSN Labs. Pvt. Ltd., 19-2009 (D. Del.) | Oct. 23, 2019 | Hon. Leonard P. Stark | Rexulti® (brexpiprazole tablets) | 7,888,362 8,349,840 8,618,109 9,839,637 10,307,419 |
| Novartis Pharms. Corp. v. Alembic Pharms. Ltd., 19-2021 (D. Del.) | Oct. 24, 2019 | Hon. Leonard P. Stark | Entresto® (sacubitril / valsartan tablets) | 8,101,659 8,796,331 8,877,938 9,388,134 |
| Otsuka Pharm. Co., Ltd. v. Zydus Pharms. (USA) Inc., 19-2024 (D. Del.) | Oct. 25, 2019 | Hon. Leonard P. Stark | Rexulti® (brexpiprazole tablets) | 7,888,362 8,349,840 8,618,109 9,839,637 10,307,419 |
| Novartis Pharms. Corp. v. Macleods Pharms. Ltd., 19-19345 (D.N.J.) | Oct. 25, 2019 | Hon. Mitchell S. Goldberg | Entresto® (sacubitril / valsartan tablets) | 8,101,659 8,877,938 9,388,134 |
| Otsuka Pharm. Co., Ltd. v. Zydus Pharms. (USA) Inc., 19-19394 (D.N.J.) | Oct. 25, 2019 | Hon. Freda L. Wolfson | Rexulti® (brexpiprazole tablets) | 7,888,362 8,349,840 8,618,109 9,839,637 10,307,419 |
| Exelixis, Inc. v. MSN Labs. Private Ltd., 19-2017 (D. Del.) | Oct. 29, 2019 | Hon. Richard G. Andrews | Cabometyx® (cabozantinib tablets) | 8,877,776 |
| Cydex Pharms., Inc. v. Lupin Ltd., 19-2043 (D. Del.) | Oct. 29, 2019 | Hon. Leonard P. Stark | Evomela® (Captisol®-enabled melphalan HCl for injection) | 9,200,088 9,493,582 |
| Genzyme Corp. v. Dr. Reddy’s Labs., Inc., 19-2045 (D. Del.) | Oct. 29, 2019 | Hon. Colm F. Connolly | Cerdelga® (eliglustat capsules) | 6,916802 7,253185 7,615573 |
| Novartis Pharms. Corp. v. Dr. Reddy’s Labs., Inc., 19-2053 (D. Del.) | Oct. 29, 2019 | Hon. Leonard P. Stark | Entresto® (sacubitril / valsartan tablets) | 8,101,659 8,796,331 8,877,938 9,388,134 |
| Otsuka Pharm. Co., Ltd. v. Macleods Pharms. Ltd., 19-2065 (D. Del.) | Oct. 30, 2019 | Hon. Leonard P. Stark | Rexulti® (brexpiprazole tablets) | 7,888,362 10,307,419 |
| Novartis Pharms. Corp. v. Mylan Pharms. Inc., 19-0201 (N.D.W.V.) | Oct. 30, 2019 | Hon. Irene M. Keeley | Entresto® (sacubitril / valsartan tablets) | 8,101,659 8,796,331 8,877,938 9,388,134 |
| Mylan Pharms. Inc. v. Merck Sharp & Dohme Corp., IPR2020-00040 (PTAB) | Oct. 30, 2019 | N/A | Januvia® (sitagliptin phosphate tablets) Janumet® (metformin HCL / sitagliptin phosphate tablets) Janumet® XR (metformin HCL / sitagliptin phosphate extended-release tablets) Juvisync® (simvastatin / sitagliptin phosphate tablets) Steglujan® (ertugliflozin / sitagliptin phosphate tablets) |
7,326,708 |
| Otsuka Pharm. Co., Ltd. v. Sandoz Inc., 19-2080 (D. Del.) | Nov. 1, 2019 | Hon. Leonard P. Stark | Rexulti® (brexpiprazole tablets) | 7,888,362 8,349,840 8,618,109 9,839,637 10,307,419 |
| Otsuka Pharm. Co., Ltd. v. Sandoz Inc., 19-3112 (D. Col.) | Nov. 1, 2019 | Hon. R. Brooke Jackson | Rexulti® (brexpiprazole tablets) | 7,888,362 8,349,840 8,618,109 9,839,637 10,307,419 |
| Viiv Healthcare Co. v. Cipla Ltd., 19-2085 (D. Del.) | Nov. 4, 2019 | Hon. Mitchell S. Goldberg | Dovato® (dolutegravir / lamivudine tablets) | 9,242,986 |
| Silvergate Pharms., Inc. v. Alkem Labs. Ltd., 19-2100 (D. Del.) | Nov. 5, 2019 | Hon. Leonard P. Stark | Epaned® (enalapril maleate for oral solution) | 9,669,008 9,808,442 10,039,745 10,154,987 |
| AstraZeneca AB v. Aurobindo Pharma USA Inc., 19-2113 (D. Del.) | Nov. 8, 2019 | Hon. Richard G. Andrews | Movantik® (naloxegol oxalate tablets) | 9,012,469 |
| IBSA Institut Biochimique SA v. Teva Pharms. USA, Inc., 19-2115 (D. Del.) | Nov. 8, 2019 | Hon. Richard G. Andrews | Tirosint® (levothyroxine sodium capsules) | 7,691,411 7,723,390 |
| Eisai R&D Management Co., Ltd. v. Shilpa Medicare Ltd., 19-19998 (D.N.J.) | Nov. 8, 2019 | Hon. Freda L. Wolfson | Lenvima® (lenvatinib mesylate capsules) | 10,259,791 |
| Aquestive Therapeutics, Inc. v. Biodelivery Sciences Int’l, Inc., 19-0505 (E.D.N.C.) | Nov. 11, 2019 | Hon. Terrence W. Boyle | Belbuca® (buprenorphine buccal film) | 8,765,167 |
| Fresenius Kabi USA, LLC v. Wockhardt USA LLC, 19-20383 (D.N.J.) | Nov. 15, 2019 | Hon. Claire C. Cecchi | Naropin® (ropivacaine HCl for injection) | 8,118,802 |
| Merz Pharms., LLC v. Annora Pharma Private Ltd., 19-2165 (D. Del.) | Nov. 20, 2019 | Hon. Richard G. Andrews | Cuvposa® (glycopyrrolate oral solution) | 7,638,552 7,816,396 |
| Merck Sharp & Dohme Corp. v. Accord Healthcare, Inc., 19-2192 (D. Del.) | Nov. 25, 2019 | Hon. Richard G. Andrews | Januvia® (sitagliptin phosphate tablets) | 7,326,708 |
| Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. v. Aurobindo Pharma USA Inc., 19-2197 (D. Del.) | Nov. 25, 2019 | Hon. Richard G. Andrews | Desyrel® (trazodone HCl tablets) | 8,133,893 |
| Vanda Pharms. Inc. v. Teva Pharms. USA, Inc., 19-2202 (D. Del.) | Nov. 26, 2019 | Hon. Colm F. Connolly | Hetlioz® (tasimelteon capsules) | 10,376,487 |
| Cipla Ltd. v. Novartis AG, 19-20810 (D.N.J.) | Nov. 26, 2019 | Hon. Stanley R. Chesler | Jadenu® (deferasirox tablets) | 9,283,209 |
| Biogen Int’l GmbH v. Cipla Ltd., 19-2210 (D. Del.) | Nov. 27, 2019 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 7,619,001 |
| Alembic Pharms. Ltd. v. Novartis Pharms. Corp. 19-20890 (D.N.J.) | Nov. 27, 2019 | Hon. Stanley R. Chesler | Jadenu® (deferasirox tablets) | 9,283,209 |
| Amneal Pharms. LLC v. Cubist Pharms. LLC, IPR2020-00193 (PTAB) | Nov. 27, 2019 | N/A | Cubicin RF® (daptomycin for injection) | 9,138,456 |
| Takeda Pharms. U.S.A., Inc. v. Mylan Pharms. Inc., 19-2216 (D. Del.) | Dec. 2, 2019 | Hon. Richard G. Andrews | Colcrys® (colchicine tablets) | 7,906,519 7,935,731 8,093,297 8,093,298 7,964,648 |
| Medicure Int’l, Inc. v. Nexus Pharms., Inc., 19-7979 (N.D. Ill.) | Dec. 5, 2019 | Hon. Sharon Johnson Coleman | Aggrastat® (tirofiban HCl for injection) | 6,770,660 |
| Chiesi USA Inc. v. Gland Pharma Ltd., 19-21204 (D.N.J.) | Dec. 9, 2019 | Hon. Madeline Cox Arleo | Kengreal® (cangrelor for injection) | 6,130,208 8,680,052 9,427,448 9,439,921 9,700,575 9,925,265 10,039,780 |
| Millennium Pharms., Inc. v. Fresenius Kabi USA, LLC, 19-2252 (D. Del.) | Dec. 10, 2019 | Hon. Colm F. Connolly | Velcade® (bortezomib for injection) | 6,713,446 6,958,319 |
| Zydus Pharms. (USA) Inc. v. Novartis Pharms. Corp., 19-21259 (D.N.J.) | Dec. 10, 2019 | Hon. Stanley R. Chesler | Jadenu® (deferasirox tablets) | 9,283,209 |
| Corcept Therapeutics, Inc. v. Teva Pharms USA, Inc., 19-21384 (D.N.J.) | Dec. 13, 2019 | Hon. Susan D. Wigenton | Korlym® (mifepristone tablets) | 10,500,216 |
| Taiho Pharm. Co., Ltd. v. Eugia Pharma Specialities Ltd., 19-2309 (D. Del.) | Dec. 19, 2019 | Hon. Colm F. Connolly | Lonsurf® (trifluridine / tipiracil tablets | RE46,284 10,138,223 |
| Janssen Pharms., Inc. v. Pharmascience Inc., 19-21590 (D.N.J.) | Dec. 19, 2019 | Hon. Claire C. Cecchi | Invega Sustenna® (paliperidone palmitate extended-release injectable suspension) | 9,439,906 |
| Mylan Institutional LLC v. Novo Nordisk A/S, IPR2020-00324 (PTAB) | Dec. 19, 2019 | N/A | Victoza® (liraglutide recombinant for injection) Saxenda® (liraglutide recombinant for injection) Ozempic® (semaglutide) |
8,114,833 |
| Janssen Pharms., Inc. v. Pharmascience Inc., 19-2313 (D. Del.) | Dec. 20, 2019 | Hon. Colm F. Connolly | Invega Sustenna® (paliperidone palmitate extended-release injectable suspension) | 9,439,906 |
| Allergan USA, Inc. v. Sun Pharm. Indus. Ltd., 19-2317 (D. Del.) | Dec. 20, 2019 | Hon. Richard G. Andrews | Vraylar® (cariprazine capsules) | 7,737,142 7,943,621 |
| Taiho Pharm. Co., Ltd. v. Accord Healthcare Inc., 19-2321 (D. Del.) | Dec. 20, 2019 | Hon. Colm F. Connolly | Lonsurf® (trifluridine / tipiracil tablets | RE46,284 9,527,833 10,457,666 |
| Allergan Sales, LLC v. Torrent Pharms. Ltd., 19-21709 (D.N.J.) | Dec. 20, 2019 | Hon. Esther Salas | Fetzima® (levomilnacipran HCl extended-release capsules) | 8,481,598 8,865,937 RE43,879 |
| Sun Pharm. Indus. Ltd. v. Novartis Pharms. Corp., 19-21733 (D.N.J.) | Dec. 20, 2019 | Hon. Claire C. Cecchi | Ciprodex® (ciprofloxacin / dexamethasone otic suspension) | 9,402,805 9,345,714 9,149,486 8,846,650 |
| Taiho Pharm. Co., Ltd. v. MSN Labs. Private Ltd., 19-2342 (D. Del.) | Dec. 23, 2019 | Hon. Colm F. Connolly | Lonsurf® (trifluridine / tipiracil tablets | RE46,284 9,527,833 |
| Taiho Pharm. Co., Ltd. v. Accord Healthcare Inc., 19-1251 (M.D.N.C.) | Dec. 23, 2019 | Hon. William L. Osteen, Jr. | Lonsurf® (trifluridine / tipiracil tablets | RE46,284 9,527,833 10,457,666 |
| Eisai R&D Management Co., Ltd. v. Sun Pharm. Indus. Ltd., 19-21857 (D.N.J.) | Dec. 23, 2019 | Hon. Freda L. Wolfson | Lenvima® (lenvatinib mesylate capsules) | 10,259,791 10,407,393 |
| Ayla Pharma LLC v. Alcon Research, LLC, IPR2020-00295 (PTAB) | Dec. 24, 2019 | N/A | Pazeo® (olopatadine HCl ophthalmic drops) | 9,533,053 |
| Taiho Pharm. Co., Ltd. v. Natco Pharma Ltd., 19-2368 (D. Del.) | Dec. 30, 2019 | Hon. Colm F. Connolly | Lonsurf® (trifluridine / tipiracil tablets | RE46,284 9,527,833 10,457,666 |
| Vanda Pharms. Inc. v. Apotex Inc., 19-2375 (D. Del.) | Dec. 30, 2019 | Hon. Colm F. Connolly | Hetlioz® (tasimelteon capsules) | 10,376,487 |
| Actelion Pharms. Ltd. v. Zydus Pharms. (USA), Inc., 19-22193 (D.N.J.) | Dec. 31, 2019 | Hon. Brian R. Martinotti | Tracleer® (bosentan tablets) | 8,309,126 |
| Celgene Corp. v. Mylan Pharms. Inc., 19-22231 (D.N.J.) | Dec. 31, 2019 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) | 7,189,740 7,465,800 7,855,217 7,968,569 8,404,717 8,530,498 8,648,095 9,056,120 9,101,621 9,101,622 |
GENERICally Speaking Winter 2020
GENERICally Speaking Hatch Waxman Bulletin Related Professionals
Christopher A. Pinahs
Partner
Haroon N. Mian
Associate
GENERICally Speaking Winter 2020
VOL. 9, NO. 4 Related Publications
Fourth Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
December 29, 2023
Corcept Therapeutics, Inc. v. Teva Pharms. USA, Inc.
GENERICally Speaking Hatch Waxman Bulletin
December 13, 2023
Acadia Pharms. Inc. v. Aurobindo Pharma Ltd.
GENERICally Speaking Hatch Waxman Bulletin
December 7, 2023
H. Lundbeck A/S v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
November 7, 2023
Eisai R&D Mgmt. Co., Ltd. v. Dr Reddy’s Labs., Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.